Biocardia Financial Statements From 2010 to 2025

BCDA Stock  USD 2.50  0.18  7.76%   
Biocardia financial statements provide useful quarterly and yearly information to potential Biocardia investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biocardia financial statements helps investors assess Biocardia's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biocardia's valuation are summarized below:
Gross Profit
-4.6 M
Market Capitalization
10.6 M
Enterprise Value Revenue
95.078
Revenue
428 K
Earnings Share
(4.03)
We have found one hundred twenty available fundamental signals for Biocardia, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Biocardia prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of January 31, 2025, Market Cap is expected to decline to about 15.4 M. In addition to that, Enterprise Value is expected to decline to about 15.6 M

Biocardia Total Revenue

407,835

Check Biocardia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocardia's main balance sheet or income statement drivers, such as Depreciation And Amortization of 91.8 K, Interest Expense of 6.6 K or Selling General Administrative of 3.3 M, as well as many indicators such as Price To Sales Ratio of 32.21, Dividend Yield of 0.27 or Days Sales Outstanding of 41.22. Biocardia financial statements analysis is a perfect complement when working with Biocardia Valuation or Volatility modules.
  
Check out the analysis of Biocardia Correlation against competitors.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

Biocardia Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.3 M3.4 M11.1 M
Pretty Stable
Other Current LiabilitiesM1.9 M1.2 M
Slightly volatile
Total Current Liabilities4.4 M4.1 M2.2 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.6 M731.1 K
Slightly volatile
Accounts Payable1.1 MM576.9 K
Slightly volatile
Cash1.2 M1.3 M9.8 M
Slightly volatile
Non Current Assets Total1.6 M1.8 M805.2 K
Slightly volatile
Non Currrent Assets Other265.9 K196.7 K105.8 K
Slightly volatile
Cash And Short Term Investments1.2 M1.3 M9.8 M
Slightly volatile
Net Receivables53.9 K56.7 K241.5 K
Slightly volatile
Common Stock Total Equity17.5 K18.4 K112.4 K
Slightly volatile
Common Stock Shares Outstanding1.4 M1.6 M2.1 M
Very volatile
Liabilities And Stockholders Equity3.3 M3.4 M11.1 M
Pretty Stable
Non Current Liabilities Total630.9 K1.1 M659.2 K
Slightly volatile
Other Current Assets436.7 K265.5 K349.1 K
Pretty Stable
Other Stockholder Equity181.8 M173.1 M88.3 M
Slightly volatile
Total Liabilities5.5 M5.3 M2.7 M
Slightly volatile
Property Plant And Equipment Gross2.5 M2.4 M875.1 K
Slightly volatile
Total Current Assets1.6 M1.7 M10.3 M
Slightly volatile
Common Stock26.2 K27.6 K114.3 K
Slightly volatile
Short Term Investments324.8 K483.5 K512 K
Pretty Stable
Current Deferred Revenue750.8 K872.9 K609.7 K
Slightly volatile
Good Will986.4 K1.1 M1.2 M
Slightly volatile
Intangible Assets3.7 M3.9 M4.3 M
Slightly volatile
Short and Long Term Debt Total1.3 M1.5 M1.2 M
Slightly volatile
Short Term Debt569.4 K599.4 K2.6 M
Slightly volatile
Other Assets141.3 K196.7 K118.3 K
Slightly volatile
Capital Surpluse163.3 M155.5 M84.1 M
Slightly volatile
Other Liabilities834.4 K794.6 K344.3 K
Slightly volatile
Property Plant Equipment2.1 MM788.7 K
Slightly volatile
Preferred Stock Total Equity36.8 M41.4 M45.2 M
Slightly volatile
Deferred Long Term Liabilities75.3 K93.2 K70.5 K
Slightly volatile
Capital Stock16.9 K21.6 K31.8 K
Slightly volatile
Capital Lease Obligations1.4 M1.5 M1.2 M
Slightly volatile

Biocardia Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization91.8 K96.6 K143.3 K
Slightly volatile
Interest Expense6.6 K6.9 K136.2 K
Very volatile
Selling General Administrative3.3 M5.1 M3.2 M
Slightly volatile
Total Revenue407.8 K429.3 K665.6 K
Pretty Stable
Other Operating Expenses14.6 M13.9 M8.7 M
Slightly volatile
Cost Of Revenue9.3 M8.9 M3.3 M
Slightly volatile
Total Operating Expenses14.6 M13.9 M8.5 M
Slightly volatile
Research Development6.1 M8.9 M5.3 M
Slightly volatile
Interest Income7.7 K8.1 K212.6 K
Very volatile
Selling And Marketing Expenses2.1 M2.4 M2.6 M
Slightly volatile
Reconciled Depreciation65.3 K75.6 K78.6 K
Pretty Stable

Biocardia Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.4 M8.5 M9.9 M
Pretty Stable
Depreciation149 K75.6 K79.9 K
Slightly volatile
Dividends Paid378 K397.9 K337.4 K
Slightly volatile
End Period Cash Flow1.2 M1.3 M9.8 M
Slightly volatile
Stock Based Compensation1.2 M1.2 M1.2 M
Slightly volatile
Net Borrowings432.6 K455.4 K3.3 M
Slightly volatile
Other Cashflows From Investing Activities15.1 M17 M18.6 M
Slightly volatile
Issuance Of Capital Stock7.6 M3.9 M6.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.2133.91324
Slightly volatile
Dividend Yield0.270.30.3312
Slightly volatile
Days Sales Outstanding41.2243.39313
Pretty Stable
Average Payables6.4 K6.8 K19.3 K
Slightly volatile
Stock Based Compensation To Revenue2.41.943.0784
Pretty Stable
Capex To Depreciation0.160.14291.0234
Slightly volatile
Payables Turnover13.089.984.0163
Slightly volatile
Sales General And Administrative To Revenue12.578.9612.3231
Slightly volatile
Research And Ddevelopement To Revenue10.4914.5812.2871
Slightly volatile
Capex To Revenue0.02750.02890.8357
Slightly volatile
Cash Per Share0.670.7409
Slightly volatile
Days Payables Outstanding35.9537.844.5 K
Pretty Stable
Intangibles To Total Assets0.50.410.382
Very volatile
Current Ratio0.350.36292
Slightly volatile
Receivables Turnover7.678.716.0546
Very volatile
Graham Number15.8116.64591
Slightly volatile
Capex Per Share0.00930.00982.2212
Slightly volatile
Average Receivables179.1 K188.6 K182.9 K
Slightly volatile
Revenue Per Share0.370.398.8362
Slightly volatile
Interest Debt Per Share1.021.0774.6537
Pretty Stable
Debt To Assets0.260.510.302
Pretty Stable
Days Of Payables Outstanding35.9537.844.5 K
Pretty Stable
Ebt Per Ebit0.820.891.0532
Pretty Stable
Quick Ratio0.350.36281
Slightly volatile
Cash Ratio0.260.28120
Slightly volatile
Days Of Sales Outstanding41.2243.39313
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.150.9235
Slightly volatile
Fixed Asset Turnover0.380.43.2206
Slightly volatile
Debt Ratio0.260.510.302
Pretty Stable
Price Sales Ratio32.2133.91324
Slightly volatile
Asset Turnover0.170.180.276
Slightly volatile

Biocardia Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.4 M16.2 M846.7 M
Slightly volatile

Biocardia Fundamental Market Drivers

Cash And Short Term Investments1.1 M

Biocardia Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biocardia Financial Statements

Biocardia stakeholders use historical fundamental indicators, such as Biocardia's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biocardia investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biocardia's assets and liabilities are reflected in the revenues and expenses on Biocardia's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biocardia. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue872.9 K750.8 K
Total Revenue429.3 K407.8 K
Cost Of Revenue8.9 M9.3 M
Stock Based Compensation To Revenue 1.94  2.40 
Sales General And Administrative To Revenue 8.96  12.57 
Research And Ddevelopement To Revenue 14.58  10.49 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.39  0.37 
Ebit Per Revenue(28.07)(26.67)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:
Check out the analysis of Biocardia Correlation against competitors.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.03)
Revenue Per Share
0.264
Quarterly Revenue Growth
(0.93)
Return On Assets
(1.16)
Return On Equity
(7.04)
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.